Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece

• Главные авторы: George Gourzoulidis (Автор), Myrto Barmpouni (Автор), Vasiliki Kossyvaki (Автор), Jeffrey Vietri (Автор), Charalampos Tzanetakos (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2023-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

ObjectiveHigher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) compared to...